Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBITDA: 2009-2024

Historic EBITDA for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $163.9 million.

  • Catalyst Pharmaceuticals' EBITDA rose 20.21% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 52.37%. This contributed to the annual value of $163.9 million for FY2024, which is 129.61% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported EBITDA of $163.9 million as of FY2024, which was up 129.61% from $71.4 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBITDA peaked at $163.9 million during FY2024, and registered a low of $39.3 million during FY2021.
  • For the 3-year period, Catalyst Pharmaceuticals' EBITDA averaged around $106.2 million, with its median value being $83.3 million (2022).
  • In the last 5 years, Catalyst Pharmaceuticals' EBITDA soared by 135.09% in 2020 and then tumbled by 47.60% in 2021.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' EBITDA stood at $75.0 million in 2020, then plummeted by 47.60% to $39.3 million in 2021, then spiked by 111.82% to $83.3 million in 2022, then declined by 14.24% to $71.4 million in 2023, then surged by 129.61% to $163.9 million in 2024.